ZBH - Zimmer Biomet Holdings, Inc.

NYSE - Nasdaq Real Time Price. Currency in USD
136.20
-1.40 (-1.02%)
As of 2:19PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close137.60
Open137.94
Bid136.40 x 800
Ask136.46 x 1200
Day's Range136.19 - 137.90
52 Week Range96.99 - 143.57
Volume374,547
Avg. Volume1,150,712
Market Cap27.963B
Beta (3Y Monthly)1.19
PE Ratio (TTM)N/A
EPS (TTM)-1.76
Earnings DateNov 5, 2019
Forward Dividend & Yield0.96 (0.72%)
Ex-Dividend Date2019-09-27
1y Target Est149.92
Trade prices are not sourced from all markets
  • Medical Products Industry Outlook: Prospects Seem Promising
    Zacks

    Medical Products Industry Outlook: Prospects Seem Promising

    Medical Products Industry Outlook: Prospects Seem Promising

  • GuruFocus.com

    Take a Sneak Peek at My Purloined Portfolio

    I like to keep tabs on what my competitors are doing, especially the competitors I respect Continue reading...

  • American City Business Journals

    Market Share: 100 new jobs in Olive Branch; more 'wash shacks' coming

    One company plans to hire 100 people in the next couple of years, at wages between $60,000 and $95,000.

  • Were Hedge Funds Right About Betting On Zimmer Biomet Holdings Inc (ZBH)?
    Insider Monkey

    Were Hedge Funds Right About Betting On Zimmer Biomet Holdings Inc (ZBH)?

    As we already know from media reports and hedge fund investor letters, hedge funds delivered their best returns in a decade. Most investors who decided to stick with hedge funds after a rough 2018 recouped their losses by the end of the second quarter. We get to see hedge funds' thoughts towards the market and […]

  • Business Wire

    Shareholder Alert: Robbins Arroyo LLP Announces Complaint Filed Against Zimmer Biomet Holdings, Inc. (ZBH)

    Shareholder rights law firm Robbins Arroyo LLP announces that a purchaser of Zimmer Biomet Holdings, Inc. filed a derivative complaint against the company's officers and directors for breach of fiduciary duties and insider trading.

  • Zimmer Biomet Holdings (NYSE:ZBH) Seems To Use Debt Quite Sensibly
    Simply Wall St.

    Zimmer Biomet Holdings (NYSE:ZBH) Seems To Use Debt Quite Sensibly

    The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

  • GlobeNewswire

    Bragar Eagel & Squire is Investigating Certain Officers and Directors of PriceSmart, Pyxus, Aclaris Therapeutics, and Zimmer Biomet Holdings and Encourages Investors to Contact the Firm

    NEW YORK, Oct. 06, 2019 -- Bragar Eagel & Squire is investigating certain officers and directors of PriceSmart, Inc. (NASDAQ: PSMT), Pyxus International, Inc. (NYSE: PYX),.

  • Technically Speaking: Is the Drop in Individual Investor Sentiment Bullish or Bearish?
    Yahoo Finance

    Technically Speaking: Is the Drop in Individual Investor Sentiment Bullish or Bearish?

    With this week’s price and news drama, market sentiment (at least as per a few readings) has gone almost to panic mode. This suggests a bounce is here or very near. The American Association of Individual Investors (AAII) poll this week saw bullish sentiment decline eight percentage points to 21.4%. That is the fewest bulls in the AAII survey since December 2018, when the market was cascading lower. Bears rose 6.2 percentage points to 39.4%, widening the spread between bulls and bears to -18 percentage points. This is not far from the pessimism we saw in early August and in December, when bears exceeded bulls by 26.5 and 27.8 percentage points, respectively.

  • Here's Why You Should Hold Zimmer Biomet (ZBH) Stock for Now
    Zacks

    Here's Why You Should Hold Zimmer Biomet (ZBH) Stock for Now

    Investor confidence continues to be high in Zimmer Biomet (ZBH), thanks to solid prospects.

  • 3 “Strong Buy” Med Tech Stocks Amid Recession Threat
    TipRanks

    3 “Strong Buy” Med Tech Stocks Amid Recession Threat

    The recession alarm bells have been sounded. Many investors fear that we are heading towards a recession as a result of the inversion of the yield curve, a key recession indicator, as well as the ongoing trade war with China According to CFO’s polled by Duke University, these fears are justified. Based on the survey, 53% of U.S. CFOs believe the market will enter into a recession by the 2020 elections. Two thirds predict a recession will come by year-end 2020.  “Business optimism has not been this low since September 2016, a time when the unemployment rate was 5%. Optimism is low in all regions of the world, which exacerbates any slowdown occurring in the US,” John Graham, a finance professor at Duke University who directed the study, stated.That being said, large-cap med tech stocks have outperformed the S&P 500 year-to-date while small and mid-cap stocks have surpassed the Russell 2000 over the same time period. With this in mind, Needham’s Michael Matson stated on September 24 that he believes 3 med tech stocks have earned a “Strong Buy” rating despite the rising recession risk. This is a rating Needham gives to stocks that have especially strong long-term growth narratives. Using data from TipRanks, we wanted to dig a little deeper to determine if the five-star analyst’s picks really are poised to outperform. Let’s dive in. Boston Scientific CorporationDespite some recent shakiness, Boston Scientific (BSX\- Get Report) has gained 19% year-to-date, with Matson expecting even more growth regardless of the economic climate. The med tech company manufactures medical devices such as defibrillators and pacemakers to provide patients with less invasive medical solutions. However, Matson does point out that one of BSX’s strengths is its structural heart products which could fuel significant sales for the company. Back in April, BSX received FDA approval for its LOTUS Edge Aortic Valve System that uses transcatheter aortic valve replacement (TAVR) technology to treat severe aortic stenosis, or the narrowing of the aortic valve opening. Adding to the good news, its WATCHMAN left atrial appendage closure device reached 100,000 patient implants globally as of September 18.       The company has also made significant progress in terms of its efforts to expand its interventional oncology, arterial and venous therapy product offerings. BSX completed its $4.2 billion acquisition of BTG plc on August 26 in order to expand its reach in these areas. “Over the longer-term, we think that the BTG deal has the potential to be accretive to BSX’s revenue growth and margins,” Matson commented. He adds that its limited capital equipment sales exposure makes it less vulnerable in a recession. As a result, the five-star analyst rated BSX a “Strong Buy” and maintained the $53 price target. He believes share prices could surge 26% over the next twelve months, which is the highest upside predicted out of all other analysts covering the stock.All in all, Wall Street echoes the analyst’s sentiment. 15 Buy ratings vs 2 Holds assigned in the last three months add up to a ‘Strong Buy’ analyst consensus. Its $49 average price target indicates 15% upside potential.See BSX’s price targets and analyst ratings on TipRanks. Zimmer Biomet HoldingsZimmer Biomet (ZBH\- Get Report) develops medical technologies to treat patients suffering from bone, joint and supporting soft tissue injuries or disorders. Similar to BSX, Matson highlights ZBH as one of his top med tech picks in spite of its recent dip as less of its sales come from capital equipment. The company, which is up 32% year-to-date, has attracted a lot of attention thanks to its new robotics system. Back in March, ZBH announced that it received FDA 501(k) clearance for its Rosa One Spine system for robotically-assisted surgery. Rosa helps surgeons perform thoracolumbar minimally invasive and complex spine procedures. Partly due to the limited launch of Rosa, ZBH saw its knee segment best growth in three years, with the company planning to increase its investments in its robotics segment in the second half of the year. “Importantly, even when excluding ROSA sales in the quarter, our global knee business delivered positive growth, accelerated growth sequentially and further narrowed our gap to market,” CEO Bryan Hanson noted.While Zimmer has been bogged down by quality and supply issues, it has made progress in resolving them. Supply chain improvements that are expected to run through the inventory channel and additional product launches could drive significant upside for the company. On September 16, Zimmer announced that it received FDA 501(k) clearance for the JuggerStitch meniscal repair device. Just a few days later, it reached a distribution agreement with Align Technology (ALGN) for its dental scanners. Based on all of the above factors, Matson picks ZBH as his second “Strong Buy” and maintained his $170 average price target. His price target is highest out of all the analysts covering ZBH and suggests 24% upside potential.The rest of the Street is on the same page. With 14 Buy ratings compared to 2 Holds and 1 Sell received in the last three months, ZBH has a ‘Strong Buy’ analyst consensus. The average price target of $152 implies 10% upside potential.   See ZBH’s price targets and analyst ratings on TipRanks. Medtronic PlcWhile Medtronic (MDT\- Get Report) shares are also down in the last five days, Matson argues that the company is still expected to see strong long-term growth on top of its 18% year-to-date jump. MDT is the largest medical device company in the world and creates medical solutions for cardiac disorders, diabetes, minimally invasive therapies and restorative therapies. In an attempt to keep up with competitors, MDT unveiled its Hugo robot-assisted surgery system on September 24. Management believes the system, which is expected to be launched outside of the U.S. next year, is more flexible and cost-effective than other technologies on the market.While some believe the financial projections for Hugo leave something to be desired, several analysts disagree. As the surgical robotics market is largely underpenetrated at about 2%, the space represents a significant opportunity for MDT. Additionally, it announced on September 23 that its Evolut Pro+ TAVR device has been approved by the FDA for use in patients at low risk from open valve replacement surgery. Evolut is an updated version of its valve product. All of these positive developments prompted Matson to pick MDT and maintain the $133 price target, the highest out of all the Wall Street analysts that have assigned a rating to the stock. His price target conveys his confidence in MDT’s ability to climb 24% over the next twelve months.In general, Wall Street takes a similar approach when it comes to MDT. It has a ‘Strong Buy’ analyst consensus as it has received 16 Buy ratings vs 5 Holds in the last three months. Shares could rise 9% in the next twelve months based on its $117 average price target.    See MDT’s price targets and analyst ratings on TipRanks.

  • PR Newswire

    Zimmer Biomet Holdings Announces Audio Webcast and Conference Call of Third Quarter 2019 Results

    WARSAW, Ind. , Sept. 23, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter sales and earnings conference call will be broadcast over the Internet on ...

  • Align Technology Inks Distribution Deal With Zimmer Biomet
    Zacks

    Align Technology Inks Distribution Deal With Zimmer Biomet

    This deal indicates Align Technology's (ALGN) commitment to strengthen its portfolio of iTero scanner and services.

  • Benzinga

    The Daily Biotech Pulse: FDA Approves Merck HIV Drugs, Five Prime CEO Quits, HTG Molecular Announces Secondary Offering

    The following is a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 19.) 10X Genomics Inc (NASDAQ: TXG ) (listed its ...

  • GlobeNewswire

    Align Technology Announces Global Distribution Agreement With Zimmer Biomet Dental For Itero Element® Intraoral Scanners

    Partners with Global Implant and Restorative Dentistry Leader to Increase Penetration of iTero Scanners SAN JOSE, Calif., Sept. 19, 2019 -- Align Technology, Inc. (NASDAQ:.

  • PR Newswire

    Zimmer Biomet Announces Multinational Distribution Agreement with Align Technology for iTero Element® Intraoral Scanners

    WARSAW, Ind., Sept. 19, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced a multinational distribution agreement with Align Technology, Inc. (ALGN), for the award-winning iTero Element family of intraoral scanners. "Zimmer Biomet is committed to offering best-in-class solutions and technology tailored to dental professionals' needs, and this partnership with Align Technology to complement our portfolio of fully digital solutions is another important step in that direction," said Pedro Malha, President, Zimmer Biomet Dental.

  • Benzinga

    Canaccord Upgrades Zimmer Biomet On Incremental Opportunities In 2020, Beyond

    The strategic and cultural changes that Zimmer Biomet had been implementing over the past 18 months now seem to have taken hold, Rose said in the upgrade note. Rose mentioned that Zimmer Biomet’s turnaround plan was focused on resolving quality and supply issues, accelerating the pace of new product launches and improving sales force morale and execution. Zimmer Biomet faces several opportunities to beat the current consensus estimates for 2020, the analyst said.

  • Zimmer Biomet's New JuggerStitch to Grow Sports Medicine Line
    Zacks

    Zimmer Biomet's New JuggerStitch to Grow Sports Medicine Line

    Zimmer Biomet's (ZBH) JuggerStitch claims to offer a less invasive, all-suture, knotless approach to meniscal repair procedures.

  • PR Newswire

    Zimmer Biomet Receives FDA Clearance of JuggerStitch™ Meniscal Repair Device

    WARSAW, Ind., Sept. 16, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, has announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the JuggerStitch™ meniscal repair device.

  • PR Newswire

    Zimmer Biomet Holdings to Present at 2019 Cantor Global Healthcare Conference

    WARSAW, Ind. , Sept. 13, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, will participate in the 2019 Cantor Global Healthcare Conference ...

  • GlobeNewswire

    ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zimmer Biomet Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zimmer Biomet Holdings, Inc. (“Zimmer” or “the Company”) (NYSE: ZBH). The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Zimmer discovered that the primary legacy Biomet manufacturing facility in Warsaw, Indiana, suffered from “systemic” quality system issues.

  • Zimmer Biomet (ZBH) Launches Persona Revision for Knee Care
    Zacks

    Zimmer Biomet (ZBH) Launches Persona Revision for Knee Care

    Zimmer Biomet (ZBH) prepares for the commercial launch of improvised knee replacement procedures through its flagship program, Persona Revision Knee System.

  • PR Newswire

    Zimmer Biomet Commences Commercial Release of Persona® Revision Knee System

    WARSAW, Ind., Sept. 9, 2019 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced FDA 510(k) clearance for the Persona® Revision Knee System for revision knee replacement procedures. The Company expects to launch the system for patients in the United States over the coming weeks.

  • Morningstar

    Turnaround Takes Hold at Zimmer

    Zimmer Biomet ZBH , the undisputed king of hip and knee implants, enjoys the fruits of a wide economic moat. Zimmer has benefited from close relationships with orthopedic surgeons who make the brand choice. High switching costs and high-touch service keep the surgeons closely tied to their primary vendor, and the surgeons bring in enough profitable procedures to keep hospital administrators at bay.

  • ACCESSWIRE

    Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Investigation Against Zimmer Biomet Holdings, Inc. (ZBH)

    NEW YORK, NY / ACCESSWIRE / September 4, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Zimmer Biomet Holdings, Inc. (“Zimmer Biomet” or the “Company”) ...

  • GlobeNewswire

    ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zimmer Biomet Holdings, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

    The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zimmer Biomet Holdings, Inc. (“Zimmer” or “the Company”) (NYSE: ZBH). The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Zimmer discovered that the primary legacy Biomet manufacturing facility in Warsaw, Indiana, suffered from “systemic” quality system issues.